Vamorolone is a Small Molecule owned by Santhera Pharmaceuticals, and is involved in 8 clinical trials, of which 5 were completed, and 3 are ongoing.

Vamorolone acts as NR3C1 agonist.  The drug candidate binds to the glucocorticoid receptor and shows a wide range of inhibitory activities on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic and non-allergic-mediated inflammation. It binds to the glucocorticoid receptor (GR) and the drug-receptor complex translocates to the nucleus and acts as transcription factor for target gene expression.

The revenue for Vamorolone is expected to reach a total of $5.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Vamorolone NPV Report.

Vamorolone was originated by ReveraGen BioPharma and is currently owned by Santhera Pharmaceuticals.

Vamorolone Overview

Vamorolone (VBP-15) is under development for the treatment of mild or moderately active ulcerative colitis, Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, asthma, chronic obstructive pulmonary disorder, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, ANCA-associated vasculitis, juvenile dermatomyositis, calpain 3 deficiency (LGMD2A), limb girdle muscular dystrophy type 2B (LGMD2B) and was under development for the treatment of sickle cell anemia, cystic fibrosis and systemic juvenile idiopathic arthritis (SJIA). It is administered orally as suspension. Vamorolone is a dissociative delta-9, 11 glucocorticoid analogue, a steroidal drug. It targets NR3C1.

Santhera Pharmaceuticals Overview

Santhera Pharmaceuticals (Santhera) develops and markets novel pharmaceutical products indicated for patients with mitochondrial and neuromuscular diseases. The company specifically focuses on the area of neuromuscular and ophthalmological conditions. The company’s lead product candidate, Raxone is developed for the treatment of Leber’s hereditary optic neuropathy (LHON) and is approved by the European Marketing Authorization. Raxone is investigated for other diseases such as Duchenne muscular dystrophy and primary progressive multiple sclerosis. Santhera’s pipeline also includes other compounds, namely, omigapil for congenital muscular dystrophies. It operates through its subsidiaries in Switzerland, Liechtenstein, Germany, Canada, the UK, Italy, the Netherlands, and the US. Santhera is headquartered in Pratteln, Switzerland.

The company reported revenues of (Swiss Francs) CHF1.6 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of CHF15 million in FY2020. The operating loss of the company was CHF56.9 million in FY2021, compared to an operating loss of CHF53.1 million in FY2020. The net loss of the company was CHF55.5 million in FY2021, compared to a net loss of CHF67.7 million in FY2020.

Quick View – Vamorolone

Report Segments
  • Innovator
Drug Name
  • Vamorolone
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Genetic Disorders
  • Hematological Disorders
  • Immunology
  • Musculoskeletal Disorders
  • Respiratory
Key Companies
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.